# Trilobio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trilobio

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.trilo.bio
- Total disclosed funding: $8M
- Latest round: Seed (May 6, 2025)
- Investors on record: 3

## About

Trilobio Inc. develops advanced automated biological solutions that enhance access to biological research and applications. Their innovative platform streamlines experiments, reducing manual efforts for users across various sectors.Trilobio Inc. specializes in automation solutions for biological research, founded in 2021 in San Francisco, US. The company has completed 2 deals, with its most recent deal occurring on May 6, 2025. In this round, Trilobio raised USD 8.000 mn in Seed funding led by Initialized Capital, with participation from Argon Ventures and Lowercarbon Capital. The founder has a background in biotechnology and has previously founded other ventures in the field.Trilobio offers a suite of fully automated biological solutions designed to democratize access to advanced biological research and applications. Their core product is a high-throughput automation platform that integrates various biological processes, enabling users to conduct experiments with minimal manual intervention. This platform caters to a diverse clientele, including research institutions, biotechnology firms, and educational organizations, addressing end-use cases such as genetic analysis, drug discovery, and synthetic biology applications. The company targets several geographical markets, including North America, Europe, and parts of Asia, where demand for automated biological solutions continues to grow.Trilobio generates revenue primarily through transactional agreements structured around subscriptions and partnerships with research institutions and commercial entities. Clients engage with the company via direct sales of their automation platform, which may include annual subscription models offering varying levels of service and support. Additionally, partnerships with biotechnology companies allow Trilobio to provide customized solutions tailored to specific research needs, creating a diversified revenue stream. The company's flagship product facilitates ongoing revenue through service contracts and maintenance agreements, contributing to a stable financial base.In May 2025, Trilobio Inc. raised USD 8.000 mn in Seed funding led by Initialized Capital, with participation from Argon Ventures and Lowercarbon Capital. The company will use the funding to expand its robotics capabilities and no-code software features, enabling integration of additional lab devices and protocols into its automated platform. Future initiatives include designing new products aimed at enhancing laboratory efficiency and expanding its market presence into Asia by late 2026.

## Funding rounds

- Seed, May 6, 2025, $8M — Initialized Capital, Lowercarbon Capital, Argon Ventures

## Investors

- Initialized Capital (https://capitalatlas.ai/funds/initialized-capital) — Seed
- Lowercarbon Capital (https://capitalatlas.ai/funds/lowercarbon-capital) — Seed
- Argon Ventures (https://capitalatlas.ai/funds/argon-ventures) — Seed